• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

良性前列腺增生患者前列腺特异性抗原及其与α1-抗糜蛋白酶分子形式水平的变化

[Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].

作者信息

Grigor'ev M E, Mazo E B, Chekhonin V P

出版信息

Urol Nefrol (Mosk). 1998 Jul-Aug(4):33-7.

PMID:9727319
Abstract

Analysis of the changes in the levels of total prostatic specific antigen (t-PSA) in patients with benign prostatic hyperplasia (BPH) shows that the patient's age, size of the prostatic gland and chronic bacterial prostatitis influence the levels of t-PSA but have no effect on the levels of PSA-ACT. The relationship between the levels of t-PSA and age in BPH patients is explained by growing mass of benign hyperplasia causing mechanical load on the intact prostatic tissue. The maximal concentration of t-PSA of 8.7 +/- 1.22 ng/ml was observed in BPH patients at the age of 61-70 years. BPH stages, chronic pyelonephritis, chronic non-bacterial prostatitis, chronic renal failure are not essential for t-PSA and PSA-ACT and can be neglected in interpretation of t-PSA values in BPH patients.

摘要

对良性前列腺增生(BPH)患者总前列腺特异性抗原(t-PSA)水平变化的分析表明,患者的年龄、前列腺大小和慢性细菌性前列腺炎会影响t-PSA水平,但对PSA-ACT水平没有影响。BPH患者中t-PSA水平与年龄之间的关系可以解释为良性增生的质量增加对完整前列腺组织造成机械负荷。在61至70岁的BPH患者中观察到t-PSA的最大浓度为8.7±1.22 ng/ml。BPH分期、慢性肾盂肾炎、慢性非细菌性前列腺炎、慢性肾衰竭对t-PSA和PSA-ACT并不重要,在解释BPH患者的t-PSA值时可以忽略不计。

相似文献

1
[Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].良性前列腺增生患者前列腺特异性抗原及其与α1-抗糜蛋白酶分子形式水平的变化
Urol Nefrol (Mosk). 1998 Jul-Aug(4):33-7.
2
The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.人腺体激肽释放酶的重要性及其在前列腺癌检测中与不同前列腺特异性抗原血清形式的相关性。
Cancer. 1998 Dec 15;83(12):2540-7.
3
Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
Eur Urol. 1997;32(3):268-72.
4
Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?α1-抗糜蛋白酶-前列腺特异性抗原(ACT-PSA):前列腺良性增生和癌鉴别诊断中的有用标志物?
Anticancer Res. 1997 Nov-Dec;17(6D):4767-70.
5
Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.在患有尿潴留和前列腺良性增生或前列腺腺癌的患者中,组织学前列腺炎的意义。
BJU Int. 2012 Apr;109(8):1194-7. doi: 10.1111/j.1464-410X.2011.10527.x. Epub 2011 Aug 18.
6
A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.一项关于使用α1-抗糜蛋白酶-前列腺特异性抗原进行前列腺癌诊断的多中心临床试验。
Prostate. 2001 May 1;47(2):77-84. doi: 10.1002/pros.1049.
7
First clinical results with Enzymun-Test for free PSA.
Anticancer Res. 1997 Jul-Aug;17(4B):2861-4.
8
[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].[使用特异性和灵敏的酶联免疫吸附测定法“E-plate EIKEN PSA”检测游离前列腺特异性抗原(PSA)、α1-抗糜蛋白酶复合PSA及游离/总PSA比值的临床应用]
Hinyokika Kiyo. 1998 Oct;44(10):755-63.
9
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.α1-抗糜蛋白酶与前列腺特异性抗原的比值在前列腺癌诊断中与总前列腺特异性抗原的关系
Anticancer Res. 2000 Nov-Dec;20(6D):4997-5001.
10
Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.经计算的快速增长型良性前列腺增生——一种发生临床前列腺癌的风险因素。
Scand J Urol Nephrol. 2002;36(5):330-8. doi: 10.1080/003655902320783827.